Olverembatinib After Failure Of Tyrosine Kinase Inhibitors, Including Ponatinib Or Asciminib JAMA Oncology Author Interviews podcast

Artwork

Cancer Jamanetwork Fitness American Medical Association JAMA Network Oncology Science Medicine JAMA

Indhold leveret af American Medical Association and JAMA Network. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af American Medical Association and JAMA Network eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

JAMA Oncology Author Interviews « »
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib

3M ago 18:46

Del

MP3•Episode hjem

Indhold leveret af American Medical Association and JAMA Network. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af American Medical Association and JAMA Network eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

Interview with Hagop Kantarjian, MD, author of Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. Hosted by Vivek Subbiah, MD. Related Content:

Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib

… continue reading

121 episoder

#Cancer #Jamanetwork #Fitness #American Medical Association #JAMA Network #Oncology #Science #Medicine #JAMA

Artwork

Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib

JAMA Oncology Author Interviews

83 subscribers

published 3M ago

Del

MP3•Episode hjem

Indhold leveret af American Medical Association and JAMA Network. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af American Medical Association and JAMA Network eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

Interview with Hagop Kantarjian, MD, author of Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. Hosted by Vivek Subbiah, MD. Related Content:

Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib

… continue reading

121 episoder

#Cancer #Jamanetwork #Fitness #American Medical Association #JAMA Network #Oncology #Science #Medicine #JAMA

Alle episoder

×

Velkommen til Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

Lyt til 500+ emner

Lyt til dette show, mens du udforsker